Daclatasvir and Rosuvastatin Tablets

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Daclatasvir may increase the blood levels of rosuvastatin. This can increase the risk of side effects such as liver damage and a rare but serious condition called rhabdomyolysis that involves the breakdown of skeletal muscle tissue. In some cases, rhabdomyolysis can cause kidney damage and even death. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Let your doctor know immediately if you have unexplained muscle pain, tenderness, or weakness during treatment with rosuvastatin or similar medications, especially if these symptoms are accompanied by fever or dark colored urine. You should also seek immediate medical attention if you develop fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide 1B1 (OATP 1B1) or breast cancer resistance protein (BCRP) transporters, such as HMG-CoA reductase inhibitors. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by daclatasvir. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP. When a single 10 mg dose of rosuvastatin was administered with daclatasvir 60 mg once daily, rosuvastatin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 2.0- and 1.6-fold, respectively.

MANAGEMENT: Caution and monitoring for adverse effects are advised during concomitant use of daclatasvir with drugs that are substrates of the OATP1B1 or BCRP transporters, particularly HMG-CoA reductase inhibitors. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.

Daclatasvir

Generic Name: daclatasvir

Brand name: Daklinza

Synonyms: n.a.

What is Daclatasvir?

Rosuvastatin Tablets

Generic Name: rosuvastatin

Brand name: Crestor, Ezallor Sprinkle

Synonyms: Rosuvastatin

What is Rosuvastatin Tablets?